One of the reasons for the failure of these trials could be their reliability on the most common hallmarks of the AD pathology, beta-amyloid (Aβ) and tau, which are still debatable whether they have any causative role in AD pathology. This evidence concerns the gene MAPT and Alzheimer disease.